LONA LeonaBio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1620463 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-313.6%
TTM EPS YoY-129.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-729.0%
ROA-457.7%
ROIC (approx.)-3,861.7%
Asset turnover—
Leverage & solvency
Liabilities / assets58.0%
Debt / equity0.00x
Current ratio4.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.49x
Accruals ratio-234.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $15.02M | $12.70M | $11.26M | $6.71M | $2.83M | $3.66M | $4.30M | $9.37M |
| SG&A expense | $6.86M | $6.58M | $6.88M | $3.77M | $4.05M | $3.63M | $5.23M | $6.20M |
| Operating income | -$21.47M | -$19.45M | -$17.21M | -$78.56M | -$6.87M | -$7.29M | -$9.54M | -$15.57M |
| Net income | -$21.16M | -$19.01M | -$32.95M | -$82.89M | -$6.61M | -$6.97M | -$9.14M | -$15.00M |
| EBITDA | -$21.27M | -$19.25M | -$16.98M | -$78.32M | -$6.67M | -$7.09M | -$9.29M | -$15.32M |
| EPS (basic) | -0.89 | -0.80 | -1.73 | — | -1.68 | -1.78 | -2.34 | — |
| EPS (diluted) | -0.89 | -0.80 | -1.73 | — | -1.68 | -1.78 | -2.34 | — |
| Weighted avg. shares (diluted) | 23.74M | 23.73M | 19.03M | — | 3.94M | 3.91M | 3.90M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $16.34M | $32.32M | $32.83M | $69.28M | $20.87M | $19.89M | $26.42M | $48.44M |
| Short-term investments | $15.97M | $18.74M | $34.85M | $19.05M | $4.35M | $9.94M | $10.25M | $2.84M |
| Current assets | $36.33M | $54.81M | $69.20M | $89.46M | $27.02M | $32.22M | $39.85M | $54.84M |
| PP&E, net | $800,000 | $1.01M | $1.24M | $1.47M | $1.72M | $1.96M | $2.20M | $2.44M |
| Total assets | $38.14M | $56.89M | $71.59M | $92.15M | $30.03M | $35.55M | $43.51M | $58.78M |
| Current liabilities | $7.33M | $7.82M | $6.67M | $47.50M | $2.79M | $2.98M | $5.49M | $13.13M |
| Total liabilities | $22.12M | $23.30M | $22.29M | $64.36M | $3.25M | $3.56M | $6.18M | $13.94M |
| Shareholders' equity | $16.02M | $33.59M | $49.30M | $27.79M | $26.79M | $31.99M | $37.33M | $44.84M |
| Shares outstanding | 9.93M | 9.42M | 9.39M | 9.34M | 3.94M | 39.44M | 39.04M | 3.90M |
| Cash flow statement | ||||||||
| Operating cash flow | -$18.89M | -$16.96M | -$20.90M | -$19.40M | -$4.67M | -$7.00M | -$14.66M | -$26.01M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$26.01M |
| Investing cash flow | $2.91M | $16.33M | -$15.54M | -$14.64M | $5.65M | $441,000 | -$7.35M | -$2.81M |
| Financing cash flow | $0 | — | — | $82.44M | $0 | — | — | $34,000 |
| Depreciation & amortization | $200,000 | $200,000 | $231,000 | $243,000 | $200,000 | $200,000 | $243,000 | $243,000 |
| Stock-based compensation | $3.59M | $3.18M | $662,000 | $1.46M | $1.41M | $1.60M | $1.64M | $2.23M |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.